Ileostomy patients with abdominal bloating
Conditions
Interventions
Taking Daokenchuto 15g/day orally for 4 weeks.
Sponsors
Sapporo Higashi Tokushukai Hospital Center for Clinical and Biomedical Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who has been ileostomy 2)Patients with abdominal bloating 3)Age: more than or equal to 20 years at the time of providing informed consent 4)Patients are male or female 5)Patients are in patients or out patients 6)Patients have ileotoma. 7)Provide written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with strangulating intestinal obstruction. 2)Patients who are administrated preparation for viable organism within 4 weeks before this study. 3)Patients who was administrated daikenchuto or any Japanese traditional herbal medicine within 4 weeks before this study 4)Virus-positive (HIV, HBV, HCN) 5)Patients have serious coexisting disease (ex. Hepatic distorder, kidney disorder, cardiac disorder, hematological disorder, or metabolic disorder) 6)Women who was lactating or pregnant or person who hope the pregnancy of the partne. 7)Unsuitability as determined by the study doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Abdominal bloating 2)Gastrointestinal symptom rating scale(GSRS) 3)Analysis of ileostomy effluent -intestinal flora -organic acid -pH | — |
Countries
Japan
Contacts
Public ContactToru Kono
Sapporo Higashi Tokushukai Hospital Center for Clinical and Biomedical Research
Outcome results
None listed